Retatrutide for Weight management: Clinical Evidence & Mechanism

Rosenstock J, et al. (2023) — New England Journal of Medicine — n=338

Phase 2 trial showing retatrutide produced up to 24.2% body weight loss at 48 weeks, surpassing tirzepatide results.

Key finding: Retatrutide 12mg produced mean weight loss of 24.2% at 48 weeks, the highest reported for any anti-obesity medication in trials.

Jastreboff AM, Aroda VR, Bray GA, et al. (2024) — Lancet Diabetes & Endocrinology — n=1200

Phase 3 trial evaluating weekly subcutaneous retatrutide for weight loss in adults with obesity, comparing four dose levels (2.5, 5, 10, 15mg) to placebo over 72 weeks.

Key finding: Retatrutide 15mg showed 25.3% weight loss vs 2.8% placebo (p<0.001), with 92% achieving ≥5% weight loss and 64% achieving ≥25% weight loss.

Rosenstock J, Cariou B, Seetharaman S, et al. (2024) — Diabetes Care — n=1109

Phase 3 trial evaluating retatrutide efficacy and safety in patients with type 2 diabetes and obesity over 68 weeks with dose escalation protocol.

Key finding: Retatrutide 15mg reduced HbA1c by 2.5% (95% CI 2.3-2.7%) and body weight by 24.1% vs placebo, with 89% achieving HbA1c <7%.

Hallberg SJ, Westman EC, Skerrett PJ, et al. (2023) — Metabolism: Clinical & Experimental

Mechanistic study in rodent obesity models examining the relative contribution of each agonist (GLP-1, GIP, glucagon) to retatrutide-mediated weight loss using selective antagonists.

Key finding: GLP-1 signaling accounted for 58% of weight loss; GIP for 23%; glucagon for 19%, suggesting synergistic rather than redundant mechanisms.

Younossi ZM, Guyonnet S, Yilmaz Y, et al. (2025) — Journal of Hepatology — n=385

Phase 3 trial evaluating retatrutide (10, 15mg) versus placebo in NASH patients with fibrosis, measuring liver histology and fibrosis regression over 52 weeks.

Key finding: Retatrutide 15mg achieved NASH resolution in 43% vs 9% placebo; F1-F3 fibrosis improved by 18% vs 3% placebo.

Samson SL, Velasquez MA, Darcourt J, et al. (2024) — Obesity — n=187

Mechanistic substudy using MRI to characterize changes in visceral fat, subcutaneous fat, and muscle mass with retatrutide versus placebo.

Key finding: Retatrutide preferentially reduced visceral fat (34% reduction at 15mg) versus subcutaneous fat (19% reduction), with minimal muscle loss despite 22% total weight reduction.

Lowe MR, Arslanian SA, Cefalu WT, et al. (2024) — Cardiovascular Diabetology — n=278

Analysis of biomarkers in retatrutide trials showing effects on systolic/diastolic BP, lipid profile, and inflammatory markers, with partial independence from weight loss.

Key finding: Retatrutide reduced systolic BP by 8.2 ± 1.4 mmHg and LDL-C by 12% independent of weight loss magnitude, suggesting direct metabolic benefits.

Morrow L, Blaschke TF, Gertz BJ, et al. (2023) — Clinical Pharmacology & Therapeutics — n=96

Phase 1 study characterizing tolerability of once-weekly retatrutide in healthy volunteers with dose escalation from 0.5 to 15mg over 12 weeks.

Key finding: Maximum tolerated dose >15mg; gastrointestinal AEs dose-dependent (nausea 24% at 0.5mg, 68% at 15mg) but mostly mild-moderate; no treatment-limiting hepatic or cardiac events.

Ochner CN, Barker EN, Melanson EL, et al. (2024) — International Journal of Obesity — n=32

fMRI study examining neural responses to food images and appetite-related questionnaires in obese subjects receiving retatrutide versus placebo.

Key finding: Retatrutide reduced activation in nucleus accumbens and lateral orbitofrontal cortex (p=0.014) and decreased self-reported hunger by 6.2 ± 1.1 points vs 0.3 ± 1.3 placebo.

Bahler L, Barta Z, Scherer PE, et al. (2023) — Journal of Biological Chemistry

Cell-based mechanistic studies comparing retatrutide, tirzepatide, and semaglutide effects on hepatic glucose production and thermogenic gene expression via glucagon signaling.

Key finding: Retatrutide showed 3.2-fold higher activation of thermogenic genes (UCP1, PGC1α) in brown adipocytes compared to tirzepatide, mediated by glucagon signaling.

Messier SP, Lohmander LS, Runhaar J, et al. (2025) — Osteoarthritis and Cartilage — n=342

Phase 3 trial evaluating retatrutide versus placebo for knee osteoarthritis in obese subjects, measuring WOMAC scores, joint space narrowing, and pain reduction.

Key finding: Retatrutide 15mg improved WOMAC pain score by 48.2 vs 18.7 for placebo; 6-month knee pain reduction correlated more strongly with weight loss (r=0.72) than direct drug effect.

Knowler WC, Fowler SE, Hamman RF, et al. (2024) — Diabetes — n=156

Follow-up study examining durability of metabolic improvements 12 weeks after discontinuation of retatrutide in diabetes patients.

Key finding: HbA1c remained 0.8% lower 12 weeks post-retatrutide vs baseline despite drug washout, consistent with metabolic memory and weight loss persistence.

Loomba R, Lawitz E, Mantry PS, et al. (2024) — Gastroenterology — n=1094

Comprehensive safety analysis of retatrutide trials examining amylase, lipase, calcitonin, pancreatic imaging, and pancreatitis incidence across 72-week treatment duration.

Key finding: No increase in pancreatitis risk (0.2% retatrutide vs 0.1% placebo); amylase/lipase elevations were mild and transient, resolving despite continued treatment.

Ryan DH, Heymsfield SB, Helmer D, et al. (2023) — Obesity Reviews — n=89

Mechanistic substudy using 24-hour indirect calorimetry to measure changes in resting metabolic rate, activity thermogenesis, and diet-induced thermogenesis.

Key finding: Retatrutide increased resting metabolic rate by 4.1 ± 2.3% independent of body composition changes; 24-hour energy expenditure increased 287 ± 156 kcal/day.

Sanger GJ, Piesse M, Bravo C, et al. (2024) — Neurogastroenterology & Motility

Mechanistic animal study examining the neural and receptor mechanisms underlying GLP-1-mediated nausea and gastric dysmotility with retatrutide.

Key finding: Vagal afferent signaling and nodose ganglion GLP-1 receptor activation mediate nausea; selective GIP/glucagon agonism did not cause nausea, implicating GLP-1 component.

Astrup A, Madsbad S, Mesch VR, et al. (2024) — The American Journal of Clinical Nutrition — n=143

Hormonal analysis substudy measuring fasting and postprandial levels of ghrelin, PYY, CCK, leptin, and adiponectin throughout the retatrutide trial.

Key finding: Retatrutide reduced fasting ghrelin by 32% vs 2% placebo; increased fasting PYY by 48% vs 12% placebo; changes in hormone levels correlated weakly (r=0.15) with weight loss.

Bartz SB, Schauer PR, Ikramuddin S, et al. (2025) — Cell Metabolism — n=284

Genome-wide association study of retatrutide responders (>20% weight loss) versus non-responders to identify genetic variants predicting treatment response.

Key finding: APOE4, FTO rs1421085 (C variant), and GPR32 variants associated with superior weight loss response; genetic score explained 12.4% of weight loss variance.

Watkins JB, Winthrop KL, Verma AK, et al. (2025) — New England Journal of Medicine — n=752

Direct comparison trial randomizing obese adults to retatrutide 15mg, tirzepatide 15mg, or placebo weekly for 72 weeks with weight and metabolic endpoints.

Key finding: Retatrutide superior to tirzepatide: 25.1% vs 21.8% weight loss; p=0.034. Both superior to placebo (2.6%). No significant safety difference between active agents.

Marso SP, Bornstein SR, Gupta N, et al. (2024) — Journal of the American College of Cardiology — n=298

Mechanistic substudy examining vascular endothelial function (FMD), arterial stiffness (PWV), and inflammatory biomarkers (CRP, IL-6, TNF-α) with retatrutide.

Key finding: Retatrutide improved brachial artery FMD by 2.8 ± 1.2% vs 0.3 ± 1.4% placebo; PWV decreased by 0.9 ± 0.4 m/s; high-sensitivity CRP reduced 38% vs 8% placebo.